Related Experiment Video

Updated: Apr 24, 2026

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.6K

Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure

Reiner Buchhorn1

  • 1Chefarzt der Klinik Kinderund Jugendmedizin, Caritas-Krankenhaus, Uhlandstr. 7, 97980 Bad Mergentheim, Germany. reiner.buchhorn@ckbm.de.

Reviews on Recent Clinical Trials
|September 9, 2014
PubMed

Insights

Propranolol shows significant benefits in treating heart failure in infants with congenital heart disease, improving clinical scores and cardiac remodeling. This beta-blocker therapy offers a safe alternative to traditional treatments, with careful dosage adjustments.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease
  • Heart Failure Management

Background:

  • Congenital heart disease (CHD) affects up to 20% of pediatric patients with heart failure, primarily due to large left-to-right shunts.
  • Heart failure significantly impacts prognosis, growth, and neurodevelopment in children.
  • Current medical therapies for pediatric heart failure, including digoxin, diuretics, and ACE-inhibitors, lack robust evidence from prospective randomized trials.

Purpose of the Study:

  • To evaluate the efficacy and safety of propranolol as a medical heart failure therapy in infants with congenital heart disease.
  • To assess the impact of propranolol on clinical heart failure scores, neurohormonal activation, heart rate variability, and cardiac remodeling.

Main Methods:

  • A prospective randomized trial (CHF-Pro-Infant) was conducted.
  • Propranolol was administered to infants with severe heart failure and elevated Pro-BNP levels.
  • Dosages were titrated based on heart rate, targeting 100-110 bpm in infants, with an average maintenance dose of 2mg/kg/day after 2-3 weeks.

Main Results:

  • Propranolol demonstrated a significant beneficial effect on the clinical heart failure score.
  • Improvements were observed in neurohormonal activation, heart rate variability, and cardiac remodeling.
  • No serious adverse events, such as worsening heart failure, severe bradycardia, or pulmonary obstruction, were reported.
  • Low-dose diuretics were used to prevent renin-angiotensin-aldosterone system activation.

Conclusions:

  • Propranolol is an effective and safe treatment for heart failure in infants with congenital heart disease.
  • This beta-blocker therapy offers a promising alternative to traditional treatments, with a favorable safety profile.
  • Careful management of diuretic use is essential to mitigate detrimental effects on cardiac remodeling.

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K
A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents06:33

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents

Published on: September 21, 2021

2.1K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K